Metahexamide
Metahexamide (INN) is an anti-diabetic drug from the group of sulfonylureas. It is long-acting and belongs to the first-generation cyclohexyl-containing sulfonylureas. It was first described in 1959.[1]
|  | |
| Names | |
|---|---|
| Preferred IUPAC name 3-Amino-N-(cyclohexylcarbamoyl)-4-methylbenzene-1-sulfonamide | |
| Identifiers | |
| 3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.008.434 | 
| KEGG | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| 
 | |
| 
 | |
| Properties | |
| C14H21N3O3S | |
| Molar mass | 311.4 g/mol | 
| Pharmacology | |
| A10BB10 (WHO) | |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references | |
References
    
- Moss JM, Delawter D (September 1959). "Metahexamide in diabetes therapy". Ann NY Acad Sci. 82 (2): 614–7. doi:10.1111/j.1749-6632.1959.tb44940.x. PMID 14424617.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

